Agilent Technologies
A
$146.93
+2.66%
Agilent Technologies is a life sciences and diagnostics company that was spun out of Hewlett-Packard in 1999 and today operates three segments — Life Sciences and Diagnostics, Agilent CrossLab (consumables and services), and Applied Markets — selling analytical instruments, consumables, software, and services to biopharmaceutical, chemical, advanced-materials, clinical, environmental, and government customers. With roughly 18,100 employees and a market capitalization near $43 billion, Agilent is a scaled, high-quality incumbent in analytical instrumentation rather than a hyper-growth disruptor, and its competitive identity rests on the stickiness of its installed base and the recurring revenue generated by its CrossLab consumables and services franchise. The current investor narrative centers on a sharp fundamental inflection: the company reported a strong quarterly beat in late May 2026 and raised its full-year profit forecast, sending the stock up sharply, while management is also betting on higher-margin pathology innovation through the Biocare Medical acquisition announced in March 2026. Debate now hinges on whether this earnings momentum is durable — supported by roughly 10% year-over-year revenue growth and expanding margins — or whether the stock has already priced in the recovery after a powerful multi-month re-rating.…
A
Agilent Technologies
$146.93
Related headlines
Investment Opinion: Should I buy A Today?
Agilent Technologies presents a compelling investment case, supported by a unanimous buy rating from 21 analysts and an average target price of $174.95, implying 19.1% upside from the current $146.93. The company has demonstrated a strong fundamental inflection, with Q2 2026 revenue growing 10.01% year-over-year to $1.835 billion and EPS jumping 60% to $1.20. Management raised full-year profit guidance, and the stock surged on the news, reflecting robust operational momentum. The core thesis is that Agilent is a high-quality, cash-generative life sciences leader with a sticky installed base and recurring revenue from consumables and services, now entering a period of accelerating growth and margin expansion.
The supporting evidence is compelling: revenue growth of 10.01% is well above the company's historical mid-single-digit pace; gross margin expanded to 54.99% from 51.92% a year ago; operating margin improved to 21.74% from 17.99%; and free cash flow is robust at $1.256 billion. The balance sheet is healthy with a debt-to-equity ratio of 0.50 and a current ratio of 1.96. The forward P/E of 21.7x is reasonable for a company with double-digit earnings growth, and the PEG ratio of 9.44, while high, reflects the recent earnings recovery. Compared to peers like Thermo Fisher and Danaher, Agilent's valuation is in line, but its growth trajectory is improving.
However, risks could invalidate the thesis. The biggest concerns are: (1) valuation is full at 31.9x trailing earnings, leaving little margin of safety; (2) China exposure could be disrupted by trade tensions; and (3) integration of Biocare Medical may not proceed smoothly. The rating would change to a Sell if revenue growth decelerates below 5% or if gross margin falls below 52%. Conversely, a Buy rating is maintained as long as growth remains above 8% and margins hold. Overall, the stock appears fairly valued to slightly undervalued relative to its growth prospects, but investors should be aware of the premium multiple and geopolitical risks.
Sign up to view all
A 12-Month Price Forecast
Agilent is in the early innings of a fundamental recovery, with revenue growth accelerating to 10% and margins expanding. The analyst community is unanimously bullish, and the average target implies nearly 20% upside. However, the stock trades at a premium valuation (31.9x trailing P/E) and faces risks from China exposure and Biocare integration. The recent pullback from the 52-week high may provide a buying opportunity, but investors should monitor upcoming earnings and geopolitical developments. I would upgrade to high confidence if Q3 results confirm sustained growth and margin expansion; I would downgrade if revenue growth falls below 7% or if China sales decline.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Agilent Technologies's 12-month outlook, with a consensus price target around $174.95 and implied upside of +19.1% versus the current price.
Average Target
$174.95
0 analysts
Implied Upside
+19.1%
vs. current price
Analyst Count
—
covering this stock
Price Range
$155 - $190
Analyst target range
Bulls vs Bears: A Investment Factors
The bull case for Agilent rests on a clear fundamental inflection: 10% revenue growth, 60% EPS growth, expanding margins, and a unanimous buy rating from 21 analysts with a $174.95 average target. The bear case centers on valuation (31.9x trailing P/E, 9.44 PEG) and the risk that the recent re-rating has already priced in the recovery, especially with the stock down 0.88% over the past month and 10.3% below its 52-week high. The most important tension is whether Agilent can sustain double-digit growth and margin expansion in the face of geopolitical headwinds and integration risk from the Biocare acquisition. Currently, the bull evidence is stronger given the recent earnings beat, raised guidance, and analyst conviction, but the valuation premium demands flawless execution. If growth decelerates or margins stall, the stock could quickly de-rate toward its 52-week low of $108.35.
Bullish
- Earnings beat and raised guidance: Agilent reported a strong quarterly beat in late May 2026 and raised its full-year profit forecast, sending the stock up sharply on May 28, 2026. This operational momentum is corroborated by Q2 2026 EPS of $1.20 versus $0.75 in Q2 2025, a 60% year-over-year increase.
- Revenue growth accelerating to 10%: Q2 2026 revenue grew 10.01% year-over-year to $1.835 billion, up from $1.668 billion in Q2 2025. This acceleration is notable for a mature instruments company and suggests the post-COVID capital equipment recovery is gaining traction.
- Margin expansion across the board: Q2 2026 gross margin expanded to 54.99% from 51.92% a year earlier, while operating margin rose to 21.74% from 17.99%. Net margin improved to 18.47% from 12.89%, demonstrating strong operating leverage on higher volumes.
- Analyst consensus is bullish with upside: All 21 analysts covering Agilent rate it a buy (recommendation mean 1.74), with an average target price of $174.95, implying 19.1% upside from the current price of $146.93. The low target of $155 still represents 5.5% upside, indicating broad-based confidence.
Bearish
- Valuation leaves little room for error: At a trailing P/E of 31.9x and forward P/E of 21.7x, Agilent trades at a premium to the broader market and its own historical average. The PEG ratio of 9.44 suggests the market is pricing in aggressive growth that may be difficult to sustain.
- Momentum has stalled recently: Despite a 31.8% six-month gain, the stock is down 0.88% over the past month and has underperformed the S&P 500 by 0.28% over the past year. The recent pullback from the 52-week high of $163.75 (reached in August 2026) signals waning momentum.
- China exposure poses geopolitical risk: Agilent generates significant revenue from China, one of its largest country concentrations. Escalating US-China trade tensions or new tariffs on scientific instruments could disrupt sales and compress margins, a risk highlighted by the company's geographic diversity.
- Integration risk from Biocare acquisition: The March 2026 acquisition of Biocare Medical is intended to accelerate growth in high-margin pathology, but integration execution is key. Any missteps could delay synergies, dilute margins, or distract management from core operations.
A Technical Analysis
Beta
1.24
1.24x market volatility
Max Drawdown
-29.9%
Largest decline past year
52-Week Range
$108-$164
Price range past year
Annual Return
+15.9%
Cumulative gain past year
| Period | A Return | S&P 500 |
|---|---|---|
| 1m | -0.9% | -1.6% |
| 3m | +13.2% | +1.3% |
| 6m | +31.8% | +13.9% |
| 1y | +15.9% | +16.3% |
| ytd | +6.5% | +12.1% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
A Fundamental Analysis
Quarterly Revenue
$1.8B
2026-04
Revenue YoY Growth
+10.0%
YoY Comparison
Gross Margin
55.0%
Latest Quarter
Free Cash Flow
$1.3B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is A Overvalued?
PE
31.9x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 16x~44x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
23.4x
Enterprise Value Multiple
Investment Risk Disclosure
Agilent's financial risks are moderate but warrant monitoring. The company carries a debt-to-equity ratio of 0.50, which is manageable, but interest expense of $25 million per quarter consumes a notable portion of operating income. More importantly, the company's valuation relies on continued earnings growth: trailing P/E is 31.9x and forward P/E is 21.7x, leaving little room for disappointment. A slowdown in revenue growth from the current 10% year-over-year pace, or a failure to sustain the recent margin expansion (gross margin 54.99% in Q2 2026), could trigger a sharp correction. Additionally, the Biocare Medical acquisition introduces integration risk; if synergies fail to materialize, margins could be diluted rather than enhanced.
Market and competitive risks are significant. Agilent operates in a highly competitive life sciences and diagnostics market, facing rivals such as Thermo Fisher Scientific and Danaher. Its beta of 1.24 means the stock is more volatile than the market, and any sector rotation away from healthcare could disproportionately impact the shares. The company's substantial exposure to China—one of its largest geographic markets—exposes it to US-China trade tensions, tariffs, and regulatory changes. Recent news highlights a potential US-Iran ceasefire extension that provided a modest tailwind for risk assets, but geopolitical uncertainty remains elevated. Furthermore, the stock has already re-rated significantly, up 31.8% over six months, and any negative surprise could lead to multiple compression.
The worst-case scenario for Agilent would involve a combination of slowing revenue growth, margin compression, and geopolitical disruptions. If China sales decline due to trade restrictions, and the Biocare integration stumbles, earnings could miss expectations, prompting analysts to downgrade the stock. In such a scenario, the shares could retest the 52-week low of $108.35, representing a 26.3% decline from the current price of $146.93. A more severe outcome, such as a global recession reducing capital spending by biopharma customers, could push the stock below $100, a 32% drop. The max drawdown over the past year was 29.87%, indicating that such a decline is within the realm of possibility. Investors should be prepared for significant downside if the growth narrative unravels.
FAQ
The key risks for Agilent include: (1) Valuation risk: at 31.9x trailing earnings, the stock is vulnerable to de-rating if growth slows; (2) Geopolitical risk: significant exposure to China could be disrupted by trade tensions or tariffs; (3) Integration risk: the Biocare Medical acquisition may not deliver expected synergies, potentially diluting margins; (4) Market risk: with a beta of 1.24, the stock is more volatile than the market and could decline disproportionately in a downturn. Additionally, the company faces competition from larger peers like Thermo Fisher and Danaher. These risks are ranked from highest to lowest severity, with valuation and geopolitical risks being the most immediate concerns.
Our 12-month forecast for Agilent includes three scenarios: a base case (50% probability) with a target range of $155-$175, reflecting continued high-single-digit revenue growth and stable margins; a bull case (30% probability) targeting $175-$190, driven by successful Biocare integration and resolution of trade tensions; and a bear case (20% probability) targeting $108-$130, if growth stalls or China sales decline. The most likely scenario is the base case, assuming revenue growth moderates to 7-8% and gross margin remains above 54%. The average analyst target of $174.95 aligns with our base case. Key catalysts include upcoming earnings and geopolitical developments.
Agilent's valuation appears fair to slightly overvalued on a trailing basis, but reasonable on a forward basis. The trailing P/E is 31.9x, while the forward P/E is 21.7x, reflecting expected earnings growth. The PEG ratio of 9.44 is high, suggesting the market is pricing in significant growth. Compared to peers in the life sciences tools sector, Agilent trades at a premium, but its improving growth trajectory and margin expansion justify some premium. The EV/EBITDA of 23.4x is also above the sector median. The market expects Agilent to sustain double-digit earnings growth, and if it delivers, the stock could be undervalued relative to its future cash flows. However, any disappointment could lead to multiple compression.
Agilent Technologies appears to be a good buy for investors with a medium-to-long-term horizon, given its strong fundamental momentum and unanimous analyst support. The stock trades at $146.93, with an average analyst target of $174.95, implying 19.1% upside. The company recently beat earnings and raised guidance, with Q2 2026 revenue growing 10.01% year-over-year and EPS up 60%. However, the valuation is full at 31.9x trailing earnings, and risks such as China exposure and integration of Biocare Medical could limit upside. For risk-averse investors, waiting for a pullback toward $130-$135 might provide a better entry point. Overall, it is a good buy for those comfortable with above-average volatility (beta 1.24) and a 12-18 month holding period.
Agilent is more suitable for a medium-to-long-term investment horizon of at least 12-18 months. The company is a mature, dividend-paying (0.68% yield) life sciences leader with a sticky customer base and recurring revenue, making it a core holding for healthcare portfolios. However, its beta of 1.24 and recent volatility (max drawdown 29.87%) mean short-term trading carries higher risk. The stock has strong earnings visibility and a history of consistent cash flow, which supports a buy-and-hold strategy. Short-term traders might capitalize on earnings-related moves, but the fundamental thesis is best realized over a longer period as the company executes on its growth initiatives and integrates Biocare.